Table 2.

Main adverse effects by treatment group.

Toxicities	R-M (n = 184 cycles)	R-MA (n = 39 cycles) cecs)	p value
Grade 3 neutropenia	3(1.6%)	6(15.4%)	0.001
Grade 4 neutropenia	2(1.1%)	17(43.6%)	< 0.001
Grade 3 thrombopenia	4(2.2%)	3(7.7%)	0.10
Grade 4 thrombopenia	2(1.1%)	20(51.3%)	< 0.001
Grade 3 anemia	1(0.5%)	5(12.8%)	0.001
Grade 4 anemia	0(0%)	4(10.3%)	0.001
Febrile neutropenia	5(2.7%)	16(41.0%)	< 0.001
Urinary tract infection	3(1.6%)	7(17.9%)	< 0.001
Pneumonia	3(1.6%)	7(17.9%)	< 0.001
Oral candidiasis	3(1.6%)	0(0%)	1.00
Sepsis	1(0.5%)	1(2.6%)	0.32
Acute infectious enteritis	1(0.5%)	0(0%)	1.00
Herpes zoster	1(0.5%)	0(0%)	1.00
Grade 3 Hepatotoxicity	3(1.6%)	3(7.7%)	0.068
Grade 4 Hepatotoxicity	1(0.5%)	0(0%)	1.00
Creatinine elevated	2(1.1%)	0(0%)	1.00
Deep vein thrombosis	0(0%)	1(2.6%)	0.18
Atrial fibrillation	0(0%)	2(5.1%)	0.03
Acute heart failure	0(0%)	1(2.6%)	0.18
Grade 4 skin rash	0(0%)	1(2.6%)	0.18

Notes R-M, combination regimen of high-dose methotrexate and rituximab; R-MA, combination regimen of rituximab, high-dose methotrexate and cytarabine.